International Journal of Radiation Oncology*Biology*Physics
Clinical investigation: Head and neckTreatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience☆
Introduction
Despite the recognized radiocurability and evidence of a dose–response relationship for nasopharyngeal carcinoma (NPC) 1, 2, 3, 4, radiotherapy (RT) treatment planning remains a great challenge in view of the close proximity of the tumor to the surrounding neural organs. Any attempt to perform dose escalation will be limited by the low radiation tolerance of the adjacent organs at risk (OAR)—namely, the brainstem, spinal cord, temporal lobes, and optic pathway. Strategies such as intracavitary brachytherapy (ICB) or stereotactic radiosurgery (STR) boost and altered fractionation RT regimens have been explored 3, 4, 5, 6, 7, 8, 9, 10, 11. However, regardless of the type of boost or fractionation regimen, treatment failure is expected to occur if target coverage is inadequate or normal tissue irradiation is excessive, a phenomenon not infrequently observed with conventional two-dimensional RT (2DRT). The reported 5-year local relapse-free survival after 2DRT is 75–95% and 45–80% in stage T1-T2 and T3-T4 patients, respectively 12, 13, 14.
Intensity-modulated radiation therapy (IMRT), by virtue of its dosimetric advantage, has gained increasing popularity in the treatment of cancers of the head-and-neck region. Although there is an appreciable number of dosimetric studies showing the advantage of IMRT over 2DRT in treatment of head-and-neck cancers, including NPC 15, 16, 17, 18, data on clinical outcome of primary treatment of NPC are limited. Encouraging results have been reported by the University of California-San Francisco (UCSF) group, with an impressive local control rate of 97% at 4 years when 70 Gy was delivered to the tumor 19, 20. Nevertheless, the question remains as to whether there is still a role of dose escalation beyond 66–70 Gy when target underdosing is no longer a confounding factor with IMRT. To address some of these issues, our center recruited 63 newly diagnosed nonmetastatic NPC patients for IMRT treatment between July 2000 and September 2002; these patients formed the basis of our analysis. In the present report, we describe our IMRT treatment technique and report on the early treatment outcome and toxicity profile of these patients. We also attempt to identify any significant prognostic factors, especially the dose–volume effect within the context of this high-precision therapy.
Section snippets
Pretreatment evaluation and patient characteristics
Between July 2000 and July 2002, 63 newly diagnosed nonmetastatic NPC patients underwent IMRT in our center. There were 48 males and 15 females, and the median age for the whole group was 48 years (range, 24–82 years). All patients were staged by a standard protocol comprising physical examination, fiber-optic nasopharyngoscopy, computed tomography (CT) of the nasopharynx and neck region, chest radiograph, and liver and bone profiles. Magnetic resonance imaging (MRI) of the nasopharynx was
Treatment outcomes
Analysis was performed in October 2003 and updated in March 2004, At a median follow-up time of 29 months (range, 7.7–44.7 months), 4 patients had developed local failure, 1 regional nodal failure, and 13 distant metastasis. The 3-year actuarial LRFS, NRFS, DMFS, and overall survival were 92%, 98%, 79%, and 90%, respectively (Fig. 2).
All 4 patients with local failures had advanced T3 or T4 disease initially. These were all in-field failures because the sites of local recurrence resided within
Discussion
Radiotherapy has been the mainstay of treatment for NPC for more than three decades. Until the early 1990s, the use of 2DRT to deliver a “tumoricidal” dose (66–70 Gy; 2 Gy per fraction; 6.6–7 weeks) to the target via laterally opposed fields had been the standard. This technique involved the manual projection of tumor volume and OARs onto the orthogonal simulation films based on bony anatomy and the employment of nonconformal shielding blocks to protect the critical structures. The obvious
Conclusion
Our experience of using IMRT treatment for a cohort of patients with early and advanced stage NPC showed a very high rate of locoregional control at early follow-up. All cases of local failures had occurred within the GTV. We found that dose escalation was possible for advanced T-stage tumors after 66 Gy delivered by IMRT, and dose escalation after 66 Gy-IMRT was a significant determinant of PFS and DMFS. Acute and late toxicities with IMRT were limited. Satisfactory dosimetric sparing of the
References (36)
- et al.
A clinical study of 407 cases of nasopharyngeal carcinoma in Hong Kong
Int J Radiat Oncol Biol Phys
(1989) - et al.
Improved local control for early T-stage nasopharyngeal carcinoma (NPC)—a tale of two hospitals
Radiother Oncol
(2000) - et al.
Intracavitary brachytherapy significantly enhances local control of early T-stage nasopharyngeal carcinomaThe existence of a dose-tumor-control relationship above conventional tumoricidal dose
Int J Radiat Oncol Biol Phys
(2000) - et al.
High-dose, high-precision treatment options for boosting cancer of the nasopharynx
Radiother Oncol
(2002) - et al.
Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinomaImpact on local control
Int J Radiat Oncol Biol Phys
(1999) - et al.
Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma
Int J Radiat Oncol Biol Phys
(2003) - et al.
Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy
Int J Radiat Oncol Biol Phys
(2002) - et al.
Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurological complications
Int J Radiat Oncol Biol Phys
(2000) - et al.
Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week)Report on 3-year tumour control and normal tissue toxicity
Radiother Oncol
(2001) - et al.
In-depth evaluation of the AJCC/UICC 1997 staging system of nasopharyngeal carcinomaPrognostic homogeneity and proposed refinements
Int J Radiat Oncol Biol Phys
(2003)
Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography
Int J Radiat Oncol Biol Phys
Retrospective analysis of 5073 patients with nasopharyngeal carcinoma treated during 1976–1985Overall survival and patterns of failure
Int J Radiat Oncol Biol Phys
Intensity-modulated radiotherapy in nasopharyngeal carcinomaDosimetric advantage over conventional plans and feasibility of dose escalation
Int J Radiat Oncol Biol Phys
Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma
Int J Radiat Oncol Biol Phys
Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer
Int J Radiat Oncol Biol Phys
Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinomaThe University of California-San Francisco experience
Int J Radiat Oncol Biol Phys
Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinomaAn update of the UCSF experience
Int J Radiat Oncol Biol Phys
A three-dimensional CT-based target definition for elective irradiation of the neck
Int J Radiat Oncol Biol Phys
Cited by (478)
Patterns of treatment failure in patients with nasopharyngeal carcinoma and salvage treatment outcome: A retrospective analysis study
2023, American Journal of Otolaryngology - Head and Neck Medicine and Surgery
- ☆
Supported by the Clinical Oncology Department Fund, Prince of Wales Hospital, Hong Kong.